126 related articles for article (PubMed ID: 32988590)
1. Small molecule inhibitors of the prostate cancer target KMT2D.
Yu Q; Liao Z; Liu D; Xie W; Liu Z; Liao G; Wang C
Biochem Biophys Res Commun; 2020 Dec; 533(3):540-547. PubMed ID: 32988590
[TBL] [Abstract][Full Text] [Related]
2. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
[TBL] [Abstract][Full Text] [Related]
4. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
[TBL] [Abstract][Full Text] [Related]
5. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling.
Zhang J; Ye Y; Xu Z; Luo M; Wu C; Zhang Y; Lv S; Wei Q
Biochem Biophys Res Commun; 2023 May; 655():35-43. PubMed ID: 36924677
[TBL] [Abstract][Full Text] [Related]
7. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.
Li W; Wu L; Jia H; Lin Z; Zhong R; Li Y; Jiang C; Liu S; Zhou X; Zhang E
Cell Mol Biol Lett; 2021 Nov; 26(1):45. PubMed ID: 34758724
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Xiong W; Deng Z; Tang Y; Deng Z; Li M
Biochem Biophys Res Commun; 2018 Sep; 504(1):129-136. PubMed ID: 30177394
[TBL] [Abstract][Full Text] [Related]
9. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
Ding B; Yan L; Zhang Y; Wang Z; Zhang Y; Xia D; Ye Z; Xu H
FEBS Open Bio; 2019 Apr; 9(4):693-706. PubMed ID: 30984543
[TBL] [Abstract][Full Text] [Related]
11. KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Sun P; Wu T; Sun X; Cui Z; Zhang H; Xia Q; Zhang D
Biomed Pharmacother; 2019 Jul; 115():108924. PubMed ID: 31100540
[TBL] [Abstract][Full Text] [Related]
12. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Ortega-Molina A; Boss IW; Canela A; Pan H; Jiang Y; Zhao C; Jiang M; Hu D; Agirre X; Niesvizky I; Lee JE; Chen HT; Ennishi D; Scott DW; Mottok A; Hother C; Liu S; Cao XJ; Tam W; Shaknovich R; Garcia BA; Gascoyne RD; Ge K; Shilatifard A; Elemento O; Nussenzweig A; Melnick AM; Wendel HG
Nat Med; 2015 Oct; 21(10):1199-208. PubMed ID: 26366710
[TBL] [Abstract][Full Text] [Related]
13. Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E; Jang Y; Ge K
Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Juhlin CC; Stenman A; Haglund F; Clark VE; Brown TC; Baranoski J; Bilguvar K; Goh G; Welander J; Svahn F; Rubinstein JC; Caramuta S; Yasuno K; Günel M; Bäckdahl M; Gimm O; Söderkvist P; Prasad ML; Korah R; Lifton RP; Carling T
Genes Chromosomes Cancer; 2015 Sep; 54(9):542-54. PubMed ID: 26032282
[TBL] [Abstract][Full Text] [Related]
15. Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods.
Li K; Li Z; Tao Y; Wang Q; Lai Y; Wu W; Peng S; Guo Z; Huang H
Future Med Chem; 2019 Dec; 11(24):3125-3137. PubMed ID: 31838901
[No Abstract] [Full Text] [Related]
16. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
Hou G; Xu W; Jin Y; Wu J; Pan Y; Zhou F
Biochem Biophys Res Commun; 2019 Nov; 519(4):747-753. PubMed ID: 31547991
[TBL] [Abstract][Full Text] [Related]
17. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Heward J; Konali L; D'Avola A; Close K; Yeomans A; Philpott M; Dunford J; Rahim T; Al Seraihi AF; Wang J; Korfi K; Araf S; Iqbal S; Bewicke-Copley F; Kumar E; Barisic D; Calaminici M; Clear A; Gribben J; Johnson P; Neve R; Cutillas P; Okosun J; Oppermann U; Melnick A; Packham G; Fitzgibbon J
Blood; 2021 Aug; 138(5):370-381. PubMed ID: 33786580
[TBL] [Abstract][Full Text] [Related]
18. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer.
Zhai Q; Luo M; Zhang Y; Zhang W; Wu C; Lv S; Wei Q
Transl Cancer Res; 2022 Aug; 11(8):2607-2621. PubMed ID: 36093518
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
